These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37439177)
1. [Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms]. Luo D; Luo J; Liang H; He Z; Chen H; Wen Z; Wang Q; Zhou X; Liu X; Xu N Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):1029-1034. PubMed ID: 37439177 [TBL] [Abstract][Full Text] [Related]
3. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms]. Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463 [TBL] [Abstract][Full Text] [Related]
4. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333 [TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting. Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517 [No Abstract] [Full Text] [Related]
6. Clinical Impact of Yönal-Hindilerden İ; Şahin E; Hindilerden F; Dağlar-Aday A; Nalçacı M Turk J Haematol; 2023 Aug; 40(3):174-182. PubMed ID: 37584526 [TBL] [Abstract][Full Text] [Related]
7. The Combination of Wu S; Luo P; Rouzi T; Yu Y; Xiong B; Wang Y; Zuo X Cancer Control; 2023; 30():10732748231163648. PubMed ID: 36895113 [TBL] [Abstract][Full Text] [Related]
8. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the Clinical Significance and Safety of Interferon in the Treatment of Chronic Myeloproliferative Tumors. Yin F; Yin J; Xu W; Li S; Zhang W; Wang J J Oncol; 2022; 2022():6551868. PubMed ID: 35615245 [TBL] [Abstract][Full Text] [Related]
10. [Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera]. Sokolova MA; Turkina AG; Melikian AL; Sudarikov AB; Treglazova SA; Shukhov OA; Gemdzhian EG; Abdullaev AО; Kovrigina AM; Misyurin AV; Pliskunova YV; Ivanova VL; Moiseeva TN Ter Arkh; 2016; 88(12):69-77. PubMed ID: 28139563 [TBL] [Abstract][Full Text] [Related]
11. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982 [TBL] [Abstract][Full Text] [Related]
13. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET). Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989 [TBL] [Abstract][Full Text] [Related]
14. [Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms]. Fu J; Xu Q; Zhao Y; Liu G; Cheng Z; Liang W; Xie X; Gu L Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(46):3727-32. PubMed ID: 26850010 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310 [TBL] [Abstract][Full Text] [Related]
16. Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms. Demiriz IŞ; Kazanci MH; Menfaatli E; Jafari-Gharabaghlou D; Zarghami N Mol Biol Rep; 2023 Jul; 50(7):5687-5695. PubMed ID: 37209326 [TBL] [Abstract][Full Text] [Related]
17. [What's new in myeloproliferative neoplasia?]. Schmidt S; Wolf D Dtsch Med Wochenschr; 2022 Mar; 147(6):306-311. PubMed ID: 35291035 [TBL] [Abstract][Full Text] [Related]
18. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351 [TBL] [Abstract][Full Text] [Related]
19. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Iványi JL; Marton E; Plander M Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365 [TBL] [Abstract][Full Text] [Related]
20. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]